000			03318cam a2200349 a 4500
003			EG-GiCUC
005			20250223031404.0
008			160106s2015 ua dh f m 000 0 eng d
040			_aEG-GiCUC _beng _cEG-GiCUC
041	0		_aeng
049			_aDeposite
097			_aM.Sc
099			_aCai01.11.28.M.Sc.2015.Sa.S
100	0		_aSamah Abdelhameed Mubarak
245	1	0	_aSafety and efficacy of combined therapy with pegylated interferon alpha-2b and ribavirin for Egyptian children with HCV infection / _cSamah Abdel Hameed Mubarak ; Supervised Hanaa Mostafa El-Karaksy , Doa`A Ahmed Essawi Saleh , Engy Adel Mohammad Mogahed
246	1	5	_aسلامة و فاعلية العلاج بالانترفيرون الفا -2بي مع وريبافيرين للاطفال المصابين بالالتهاب الكبدى فيروس س
260			_aCairo : _bSamah Abdelhameed Mubarak , _c2015
300			_a119 P. : _bcharts , facsimiles ; _c25cm
502			_aThesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Pediatrics
520			_aThe study was performed on 66 pediatric patients (3-18 years of age), of both sexes, infected with HCV GT4. Children were treated with PEG IFN Ü 2b in a dose of 60 æg/m2, given as subcutaneous injection once weekly and RBV in a dose of 15 mg/kg in 2 divided doses orally, daily. Treatment outcome was assessed by the absence of detectable viral RNA in blood 24 weeks after end of treatment, i.e., sustained virological response (SVR). Safety was assessed by performing specific investigations, weight and height measurements and questionnaires directed to the patients at specific intervals. Results: Forty three out of the 66 included patients (65.2%) were males. Mean age of the patients at the time of enrollment in the study was 10.9 + 3.5 years. SVR was achieved in 28 patients (42.4%). Comparing the group of responders to the non responders, history of treated malignancies was significantly commoner in non responders group (P= 0.03), responders had significantly higher levels of absolute neutrophilic count and lower levels of GGT (P= 0.009 and 0.003 respectively). HCV PCR level was significantly lower in responders (P=0.03). Fever was the most frequently reported side effect occurring in 98.5% of the patients followed by musculoskeletal symptoms. Neutropenia was observed in 36 patients (54.6%) which necessitated treatment discontinuation in only one patient. Seventy percent of children, who received the combined therapy for a total of 48 weeks, showed a drop in both weight and height percentiles at the end of the 48 weeks. Conclusion: The currently available treatment, PEG-IFNÜ 2b and RBV, for HCV GT 4 in pediatric patients has modest SVR of 42.4% with numerous adverse events necessitating meticulous monitoring to optimize care of the patients. Side effects could be managed with dose modifications and specific treatment when necessary
530			_aIssued also as CD
653		4	_aHCV
653		4	_aINF
653		4	_aRBV
700	0		_aDoa`A Ahmed Essawi Saleh , _eSupervisor
700	0		_aEngy Adel Mohammad Mogahed , _eSupervisor
700	0		_aHanaa Mostafa Elkaraksy , _eSupervisor
856			_uhttp://172.23.153.220/th.pdf
905			_aEnas _eCataloger
905			_aNazla _eRevisor
942			_2ddc _cTH
999			_c54316 _d54316